SAN DIEGO, Dec. 15, 2010 /PRNewswire/ -- Sequenom, Inc. (Nasdaq: SQNM) today announced the acceptance of a manuscript describing results from the R&D "locked-assay" verification study conducted by the company's wholly-owned subsidiary, Sequenom Center for Molecular Medicine.
Details of this study entitled "Noninvasive Detection of Fetal Trisomy 21 by Plasma DNA Sequencing in a Clinical Setting" have been embargoed until publication in the American Journal of Obstetrics and Gynecology.
About Sequenom Center for Molecular Medicine
Sequenom Center for Molecular Medicine (Sequenom CMM®) is a CAP accredited and CLIA-certified specialty reference laboratory dedicated to the development and commercialization of laboratory-developed genetic testing services for prenatal and eye conditions. Utilizing innovative proprietary technologies, Sequenom CMM provides genetic testing results services upon orders from physicians. Working closely with key opinion leaders and experts in obstetrics, retinal care and genetics, Sequenom CMM scientists use a variety of sophisticated and cutting-edge methodologies in the development and validation of laboratory tests. Sequenom CMM is changing the landscape in genetic diagnostics. Visit http://www.scmmlab.com for more information on laboratory services.
Sequenom, Inc. (NASDAQ: SQNM) is a life sciences company committed to improving healthcare through revolutionary genetic analysis solutions. Sequenom develops innovative technology, products and diagnostic tests that target and serve discovery and clinical research, and molecular dia
|SOURCE Sequenom, Inc.|
Copyright©2010 PR Newswire.
All rights reserved